BB Biotech AG

SW:BION Switzerland Biotechnology
Market Cap
$2.81 Billion
CHF2.58 Billion CHF
Market Cap Rank
#37536 Global
#131 in Switzerland
Share Price
CHF46.70
Change (1 day)
+1.30%
52-Week Range
CHF25.25 - CHF49.50
All Time High
CHF78.42
Categories
Companies in Switzerland Biotechnology
About

BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domicile… Read more

BB Biotech AG (BION) - Net Assets

Latest net assets as of June 2025: CHF1.84 Billion CHF

Based on the latest financial reports, BB Biotech AG (BION) has net assets worth CHF1.84 Billion CHF as of June 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF1.84 Billion) and total liabilities (CHF2.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CHF1.84 Billion
% of Total Assets 99.87%
Annual Growth Rate 0.79%
5-Year Change -41.38%
10-Year Change -42.53%
Growth Volatility 25.93

BB Biotech AG - Net Assets Trend (2003–2024)

This chart illustrates how BB Biotech AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for BB Biotech AG (2003–2024)

The table below shows the annual net assets of BB Biotech AG from 2003 to 2024.

Year Net Assets Change
2024-12-31 CHF2.29 Billion -1.59%
2023-12-31 CHF2.32 Billion -13.51%
2022-12-31 CHF2.69 Billion -18.33%
2021-12-31 CHF3.29 Billion -15.67%
2020-12-31 CHF3.90 Billion +14.95%
2019-12-31 CHF3.39 Billion +17.63%
2018-12-31 CHF2.88 Billion -18.49%
2017-12-31 CHF3.54 Billion +17.84%
2016-12-31 CHF3.00 Billion -24.51%
2015-12-31 CHF3.98 Billion +13.90%
2014-12-31 CHF3.49 Billion +64.83%
2013-12-31 CHF2.12 Billion +71.71%
2012-12-31 CHF1.23 Billion +23.19%
2011-12-31 CHF1.00 Billion -18.88%
2010-12-31 CHF1.23 Billion -18.56%
2009-12-31 CHF1.52 Billion +0.76%
2008-12-31 CHF1.50 Billion -14.85%
2007-12-31 CHF1.77 Billion -21.56%
2006-12-31 CHF2.25 Billion -1.18%
2005-12-31 CHF2.28 Billion +19.09%
2004-12-31 CHF1.91 Billion -1.28%
2003-12-31 CHF1.94 Billion --

Equity Component Analysis

This analysis shows how different components contribute to BB Biotech AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 219.3% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CHF2.31 Billion 101.25%
Common Stock CHF11.08 Million 0.48%
Total Equity CHF2.29 Billion 100.00%

BB Biotech AG Competitors by Market Cap

The table below lists competitors of BB Biotech AG ranked by their market capitalization.

Company Market Cap
COGNIZANT TECH SO-A - Dusseldorf Stock Exchang
DU:COZ
 		$495.33K
Encanto Potash Corp
PINK:ENCTF
 		$495.39K
CHEFS' WAREHOUSE
BE:2CF
 		$495.51K
JPMorgan Equity And Options Total Return ETF
BATS:JOYT
 		$495.69K
Greenkraft Inc
PINK:GKIT
 		$494.89K
FIRST SENSOR - Dusseldorf Stock Exchang
DU:SIS
 		$494.88K
Czerwona Torebka
WAR:CZT
 		$494.63K
Propell Holdings Ltd
AU:PHL
 		$494.63K

Equity Growth Attribution

This analysis shows how different factors contributed to changes in BB Biotech AG's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 2,323,217,000 to 2,286,292,000, a change of -36,925,000 (-1.6%).
  • Net income of 75,899,000 contributed positively to equity growth.
  • Dividend payments of 109,692,000 reduced retained earnings.
  • Share repurchases of 3,132,000 reduced equity.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CHF75.90 Million +3.32%
Dividends Paid CHF109.69 Million -4.8%
Share Repurchases CHF3.13 Million -0.14%
Total Change CHF- -1.59%

Book Value vs Market Value Analysis

This analysis compares BB Biotech AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.12x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 3.13x to 1.12x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2003-12-31 CHF14.94 CHF46.70 x
2004-12-31 CHF15.26 CHF46.70 x
2005-12-31 CHF18.93 CHF46.70 x
2006-12-31 CHF18.91 CHF46.70 x
2007-12-31 CHF16.61 CHF46.70 x
2008-12-31 CHF17.00 CHF46.70 x
2009-12-31 CHF18.29 CHF46.70 x
2010-12-31 CHF15.64 CHF46.70 x
2011-12-31 CHF13.99 CHF46.70 x
2012-12-31 CHF21.06 CHF46.70 x
2013-12-31 CHF37.18 CHF46.70 x
2014-12-31 CHF61.65 CHF46.70 x
2015-12-31 CHF71.21 CHF46.70 x
2016-12-31 CHF54.34 CHF46.70 x
2017-12-31 CHF63.93 CHF46.70 x
2018-12-31 CHF52.07 CHF46.70 x
2019-12-31 CHF61.25 CHF46.70 x
2020-12-31 CHF70.18 CHF46.70 x
2021-12-31 CHF59.31 CHF46.70 x
2022-12-31 CHF48.52 CHF46.70 x
2023-12-31 CHF42.36 CHF46.70 x
2024-12-31 CHF41.70 CHF46.70 x

Capital Efficiency Dashboard

This dashboard shows how efficiently BB Biotech AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 3.32%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 67.99%
  • • Asset Turnover: 0.05x
  • • Equity Multiplier: 1.05x
  • Recent ROE (3.32%) is below the historical average (6.10%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2003 9.25% 92.67% 0.10x 1.02x CHF-14.59 Million
2004 10.59% 94.90% 0.11x 1.00x CHF11.31 Million
2005 13.95% 95.59% 0.13x 1.10x CHF90.00 Million
2006 13.20% 93.50% 0.12x 1.13x CHF72.11 Million
2007 -15.02% -21081.10% 0.00x 1.18x CHF-442.13 Million
2008 3.01% 64.39% 0.04x 1.08x CHF-105.13 Million
2009 2.42% 67.46% 0.04x 1.00x CHF-115.00 Million
2010 -11.85% 0.00% -0.10x 1.12x CHF-269.83 Million
2011 -6.50% 0.00% 0.00x 1.15x CHF-165.31 Million
2012 29.81% 97.62% 0.27x 1.11x CHF244.43 Million
2013 43.98% 99.35% 0.42x 1.04x CHF719.95 Million
2014 42.09% 99.58% 0.42x 1.01x CHF1.12 Billion
2015 16.41% 99.03% 0.16x 1.04x CHF255.00 Million
2016 -26.71% 0.00% -0.25x 1.07x CHF-1.10 Billion
2017 19.43% 99.20% 0.19x 1.03x CHF333.64 Million
2018 -16.34% 0.00% -0.15x 1.07x CHF-759.79 Million
2019 19.97% 98.86% 0.19x 1.05x CHF338.13 Million
2020 17.78% 98.85% 0.18x 1.02x CHF302.42 Million
2021 -12.33% 0.00% -0.11x 1.11x CHF-733.16 Million
2022 -13.32% 0.00% -0.12x 1.14x CHF-626.43 Million
2023 -8.89% -590305.71% 0.00x 1.14x CHF-438.93 Million
2024 3.32% 67.99% 0.05x 1.05x CHF-152.73 Million

Industry Comparison

This section compares BB Biotech AG's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $101,747,617
  • Average return on equity (ROE) among peers: -286.42%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
BB Biotech AG (BION) CHF1.84 Billion 9.25% 0.00x $495.17K
Newron Pharmaceuticals SpA (NWRN) $67.72 Million -7.80% 0.08x $317.49 Million
Spexis AG (SPEX) $2.29 Million -857.53% 6.33x $4.21 Million
Xlife Sciences AG (XLS) $235.23 Million 6.08% 1.08x $70.33 Million